keyword
MENU ▼
Read by QxMD icon Read
search

Asthma immunotherapy

keyword
https://www.readbyqxmd.com/read/29046189/high-adherence-to-subcutaneous-immunotherapy-in-a-real-life-study-from-a-large-tertiary-medical-center
#1
Aslı Gelincik, Semra Demir, Müge Olgaç, Halim İşsever, Bayerma Khishigsuren, Ferhan Özşeker, Bahauddin Çolakoğlu, Suna Büyüköztürk
BACKGROUND: Studies on real-life adherence to subcutaneous allergen immunotherapy (SCIT) for respiratory allergy are scarce. The aim of this study was to evaluate adherence to SCIT. METHODS: The patients prescribed SCIT for allergic rhinitis and/or asthma in 2009-2011 were contacted in 2014 and asked whether they completed at least the 3 years of SCIT and/or whether they suspended the treatment for at least 2 months. The Total Symptom Score-6, visual analog scale (VAS), asthma control test (ACT), medication scores, quality of life (QoL) scores, and immunotherapy satisfaction scores with VAS obtained before the initiation of SCIT in the first year and at the end of SCIT were compared...
November 1, 2017: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/29038166/why-and-how-to-step-down-chronic-asthma-drugs
#2
REVIEW
Michael R Gionfriddo, John B Hagan, Matthew A Rank
Asthma is a common chronic airways disease. The goal of asthma management is to control symptoms while minimizing the side effects of treatment. Following a period of stable asthma, clinicians should consider stepping down treatment. This approach is recommended by current guidelines. Step-down has been studied for several types of asthma drug regimens, and certain approaches may have lower risk than others. Systematic reviews of multiple trials support the following specific step-down approaches: optimizing inhaled corticosteroid dosing when stepping down oral corticosteroid, reducing inhaled corticosteroid from a higher dose, lowering inhaled corticosteroid-long acting bronchodilator (ICS-LABA) dose while adding ICS-LABA on-demand, adding leukotriene receptor antagonist (LTRA) while lowering inhaled corticosteroid dose, and using allergen immunotherapy when reducing inhaled corticosteroid from a higher dose...
October 16, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/29034146/course-of-respiratory-allergy-by-treatment-strategy-based-on-german-routine-data
#3
Ann-Kathrin Weschenfelder, Ludger Klimek, Norbert Mülleneisen, Harald Renz, Wolfgang Wehrmann, Thomas Werfel, Eckard Hamelmann, Jürgen Wasem, Janine Biermann
PURPOSE: Allergic respiratory diseases represent a global health problem. The two major treatment strategies are symptom treatment and specific immunotherapy (SIT). SIT is considered the only causal treatment option available with the ability to alter the course of the disease. This study aims to describe the course of disease and medication of respiratory allergy across treatment strategies and disease groups. METHODS: The analysis is based on routine data from a German statutory health insurance...
2017: Allergo Journal International
https://www.readbyqxmd.com/read/29032417/clinical-evaluation-for-sublingual-immunotherapy-with-dermatophagoides-farinae-drops-in-adult-patients-with-allergic-asthma
#4
C Zhong, W Yang, Y Li, L Zou, Z Deng, M Liu, X Huang
PURPOSE: The efficacy and safety of sublingual immunotherapy (SLIT) in house dust mite-induced allergic asthma (AA) have yet to be firmly established, especially in adult patients. Our objective is to evaluate the efficacy of SLIT with Dermatophagoides farinae drops in adult patients with AA. METHODS: One hundred and thirty-four adult patient data with house dust mite (HDM)-induced AA who had been treated for 2 years were collected. These patient data that we collected were divided into the SLIT group (n = 85) and control group (n = 49)...
October 14, 2017: Irish Journal of Medical Science
https://www.readbyqxmd.com/read/28983485/anti-ige-treatment-for-disorders-other-than-asthma
#5
REVIEW
Jeffrey Stokes
Immunoglobulin E (IgE) plays a key role in the pathogenesis of many allergic diseases. Thus, IgE-mediated immunologic pathways are an attractive target for intervention in allergic diseases. Omalizumab is a recombinant humanized monoclonal antibody that binds IgE and has been used treat allergic asthma for over a decade. Currently, omalizumab is approved for the treatment of both allergic asthma and chronic spontaneous urticaria. Since IgE plays a critical role in other allergic diseases, anti-IgE therapy has been evaluated in other allergic diseases in small clinical trials and case reports...
2017: Frontiers in Medicine
https://www.readbyqxmd.com/read/28979688/the-role-of-il-25-in-the-reduction-of-oxidative-stress-and-the-apoptosis-of-airway-epithelial-cells-with-specific-immunotherapy-in-an-asthma-mouse-model
#6
Xiefang Yuan, Eryi Wang, Xiaojun Xiao, Junyi Wang, Xiaomeng Yang, Pingchang Yang, Guoping Li, Zhigang Liu
Oxidative stress and cell apoptosis play important roles in the pathogenesis of asthma. Specific immunotherapy (SIT) is the only curative approach for asthma and is effective at decreasing asthmatic oxidation and cell apoptosis, but the mechanisms remain unclear. In this study, by using in vivo and in vitro models, we indirectly demonstrated that SIT alleviated the apoptosis and oxidative stress of bronchial epithelial cells in an asthma model through regulating interleukin (IL)-25. Female BALB/c mice were used for an asthma model induced by exposure to house dust mite (HDM) extracts as allergens...
2017: American Journal of Translational Research
https://www.readbyqxmd.com/read/28978148/allergen-specific-immunotherapy-enhanced-defense-against-bacteria-via-tgf-%C3%AE-1-induced-cyp27b1-in-asthma
#7
Junyi Wang, Xiaoyu Liu, Hui Wang, Yin Li, Nan Lan, Xiefang Yuan, Min Wu, Zhigang Liu, Guoping Li
Allergen specific immunotherapy (SIT) is the only specific treatment of allergic diseases at present. How SIT impacts pulmonary innate immunity against bacteria currently remains unclear. In this study, dust mite extracts (HDM)-sensitized mice were immunized with a subcutaneous injection of HDM. These mice were then challenged with an intranasal administration of HDM. After the last challenge, mice were infected with an intranasal instillation with P. aeruginosa (P.a). We measured the score of tissue inflammation, the expression of cathelicidin-related antimicrobial peptide (CRAMP) and 25-Hydroxyvitamin D-1Alpha-hydroxylase (CYP27B1) in lung...
September 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28968272/preventing-new-sensitization-and-asthma-onset-by-allergen-immunotherapy-the-current-evidence
#8
Ulrich Wahn
PURPOSE OF REVIEW: Specific allergen immunotherapy is considered a key candidate for a successful preventive intervention in atopic diseases. The strong association of atopic manifestations such as rhinitis and asthma with atopic sensitizations (specific serum IgE) provide a rationale for early intervention in childhood and adolescence. RECENT FINDINGS: Currently, the documentation of the disease-modifying intervention effects is limited to the secondary prevention of asthma symptoms in children with allergic rhinoconjunctivitis...
September 28, 2017: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28964530/efficacy-and-safety-of-subcutaneous-and-sublingual-immunotherapy-for-allergic-rhinoconjunctivitis-and-asthma
#9
REVIEW
Christopher R Roxbury, Sandra Y Lin
Allergic rhinitis is often associated with asthma and has significant impacts on health care costs and productivity in the United States. Although allergen avoidance and pharmacotherapy are effective, allergen-specific immunotherapy is the only treatment that may lead to improved allergy symptoms even after treatment is discontinued. Subcutaneous immunotherapy has been the mainstay of allergen-specific immunotherapy in the United States for decades, but sublingual immunotherapy has recently become available...
September 27, 2017: Otolaryngologic Clinics of North America
https://www.readbyqxmd.com/read/28964528/immunotherapy-treating-with-fewer-allergens
#10
REVIEW
Cecelia Damask
Polysensitization, sensitization to more than one allergen, is a common feature of patients with allergic rhinitis, and may be a risk factor for subsequent development of allergic diseases, especially allergic asthma. However, a polysensitized patient does not necessarily have polyallergy, a documented, causal relationship between exposure to 2 or more specific, sensitizing allergens and the subsequent occurrence of relevant clinical symptoms of allergy. Allergen immunotherapy treatment strategy for the polysensitized patient in Europe is to treat the single or 2 most clinically relevant allergen(s), whereas patients in the United States are usually treated for all potential clinically relevant allergens...
September 27, 2017: Otolaryngologic Clinics of North America
https://www.readbyqxmd.com/read/28960180/salsola-kali-cross-reacts-extensively-with-salsola-imbricata
#11
M Al-Ahmad, T Rodriguez-Bouza, N Fakim, F Pineda
BACKGROUND: There are no studies on the cross-reactivity between Salsola kali and Salsola imbricata pollens. The main goal is to compare the degree of the cross-reactivity between Salsola kali and Salsola imbricata, and secondly to compare the various common allergen components between Salsola kali and Salsola imbricata. METHODS: Serum from rhinitis patients with or without asthma living in Kuwait presenting with a positive skin test to Salsola kali were obtained...
September 29, 2017: Journal of Investigational Allergology & Clinical Immunology
https://www.readbyqxmd.com/read/28950285/could-sublingual-immunotherapy-affect-oral-health-in-children-with-asthma-and-or-allergic-rhinitis-sensitized-to-house-dust-mite
#12
Ayca Kiykim, Gonca Mumcu, Ismail Ogulur, Elif Karakoc-Aydiner, Haner Direskeneli, Safa Baris, Hasret Cagan, Ahmet Ozen
BACKGROUND: Sublingual immunotherapy (SLIT) has been successfully employed in IgE-mediated respiratory allergies. However, it is not known whether the modulation of immune responses in the sublingual area during SLIT has any deleterious effect on oral health. We sought to determine the oral health prospectively in children receiving SLIT for house dust mite allergy. MATERIAL AND METHODS: Eighteen children with allergic asthma and/or rhinitis and 31 age-matched healthy controls (HC) were included in an open-labeled trial...
September 27, 2017: International Archives of Allergy and Immunology
https://www.readbyqxmd.com/read/28950273/venom-immunotherapy-in-high-risk-patients-the-advantage-of-the-rush-build-up-protocol
#13
Yossi Rosman, Ronit Confino-Cohen, Arnon Goldberg
BACKGROUND: Venom immunotherapy (VIT) is considered to be the gold standard treatment for patients with hymenoptera venom allergy. This treatment induces systemic reactions (SR) in a significant number of patients. OBJECTIVE: To evaluate the outcome of VIT in patients with known risk factors for VIT-induced SR and to compare rush VIT (RVIT) and conventional VIT (CVIT). METHODS: All of the patients who received VIT and had at least one of the following risk factors were included: current cardiovascular disease, uncontrolled asthma, high basal serum tryptase, current treatment with β-blockers or angiotensin-converting enzyme inhibitors, and age >70 or <5 years...
September 27, 2017: International Archives of Allergy and Immunology
https://www.readbyqxmd.com/read/28936430/corrigendum-subcutaneous-and-sublingual-immunotherapy-in-allergic-asthma-in-children
#14
Sophia Tsabouri, Antigoni Mavroudi, Gavriela Feketea, George V Guibas
[This corrects the article on p. 82 in vol. 5, PMID: 28484690.].
2017: Frontiers in Pediatrics
https://www.readbyqxmd.com/read/28932386/erratum-to-allergen-immunotherapy-for-allergic-asthma-protocol-for-a-systematic-review
#15
Sangeeta Dhami, Ulugbek Nurmatov, Ioana Agache, Susanne Lau, Antonella Muraro, Marek Jutel, Graham Roberts, Cezmi Akdis, Matteo Bonini, Moises Calderon, Thomas Casale, Ozlem Cavkaytar, Linda Cox, Pascal Demoly, Breda Flood, Eckard Hamelmann, Kenji Izuhara, Ömer Kalayci, Jörg Kleine-Tebbe, Antonio Nieto, Nikolaos Papadopoulos, Oliver Pfaar, Lanny Rosenwasser, Dermot Ryan, Carsten Schmidt-Weber, Stan Szefler, Ulrich Wahn, Roy-Gerth van Wijk, Jamie Wilkinson, Aziz Sheikh
[This corrects the article DOI: 10.1186/s13601-016-0094-y.].
2017: Clinical and Translational Allergy
https://www.readbyqxmd.com/read/28902467/eaaci-guidelines-on-allergen-immunotherapy-prevention-of-allergy
#16
REVIEW
Susanne Halken, Desiree Larenas-Linnemann, Graham Roberts, Moises A Calderón, Elisabeth Angier, Oliver Pfaar, Dermot D Ryan, Ioana Agache, Ignacio J I J Ansotegui, Stefania Arasi, George Du Toit, Montserrat Fernandez-Rivas, Roy Geerth van Wijk, Marek Jutel, Jörg Kleine-Tebbe, Susanne Lau, Paolo M Matricardi, Giovanni B Pajno, Nikolaos G Papadopoulos, Martin Penagos, Alexandra F Santos, Gunter J Sturm, Frans Timmermans, R Van Ree, Eva-Maria Varga, Ulrich Wahn, Maria Kristiansen, Sangeeta Dhami, Aziz Sheikh, Muraro Antonella
Allergic diseases are common and frequently coexist. Allergen immunotherapy (AIT) is a disease-modifying treatment for IgE-mediated allergic disease with effects beyond cessation of AIT that may include important preventive effects. The European Academy of Allergy and Clinical Immunology (EAACI) has developed a clinical practice guideline to provide evidence-based recommendations for AIT for prevention of i) development of allergic comorbidities in those with established allergic diseases, ii) development of first allergic condition and iii) allergic sensitization...
September 13, 2017: Pediatric Allergy and Immunology
https://www.readbyqxmd.com/read/28900663/-costs-of-allergic-diseases-and-saving-potential-by-allergen-specific-immunotherapy-a-personal-assessment
#17
REVIEW
L Klimek, A M Chaker, R Mösges
BACKGROUND: The burden of allergic diseases is of particular relevance for the economy and the social welfare and health insurance framework. Allergic rhinitis (AR) has a life-time prevalence of approximately 30% and is one of the most common chronic diseases with considerable socioeconomic impact thus leading to substantial direct, indirect and intangible costs. This article explores the common hypothesis that allergen-specific immunotherapy (ASIT) saves national economic expenses in the long term in comparison to other standard symptomatic treatment or no therapy...
September 12, 2017: HNO
https://www.readbyqxmd.com/read/28884988/assessment-of-allergen-specific-ige-by-immunoblotting-method-in-atopic-dermatitis
#18
M R Bonyadi, D Hassanzadeh, N Seyfizadeh, S Borzoueisileh
Background and Objectives. Stimulating the immune system by exposure to various allergens to produce specific IgE has a significant role in the pathogenesis of atopic dermatitis. Identifying disease-causing allergens, prevention of exposure to those allergens, and immunotherapy will play an important role in the treatment of Atopic Disease. The purpose of this study was to determine the common allergens of northwest of Iran in patients with atopic dermatitis that are resistant to treatment. Materials and methods...
September 2017: European Annals of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28859707/quality-of-life-outcomes-in-patients-who-underwent-subcutaneous-immunotherapy-and-sublingual-immunotherapy-in-a-real-world-clinical-setting
#19
Theresa Schwanke, Eugene Carragee, Maria Bremberg, William R Reisacher
OBJECTIVE: To compare changes in quality of life (QOL) that resulted from sublingual immunotherapy (SLIT) and subcutaneous immunotherapy (SCIT) in a real-world clinical setting. BACKGROUND: SLIT is established as a viable alternative to SCIT for the treatment of allergic rhinitis. Although comparative trials are increasingly available, few studies have examined QOL outcomes between these two treatments. METHODS: One hundred and five participants who underwent immunotherapy for airborne allergies were enrolled in this prospective, single-center study...
September 1, 2017: American Journal of Rhinology & Allergy
https://www.readbyqxmd.com/read/28853977/immunotherapy-of-house-dust-mite-allergy
#20
Lin Yang, Rongfei Zhu
House dust mite (HDM) is a predominant source of indoor aeroallergen worldwide, which induces allergic diseases including allergic rhinoconjunctivitis, allergic asthma, atopic eczema and other allergic skin diseases. Allergen specific immunotherapy (AIT) is the only potential disease-modifying treatment of HDM allergic subjects. However, AIT remains underused due to no universally accepted allergen standardization and a shortage of rigorous clinical studies to confirm safety and efficacy. With the effort of doctors and researchers in allergy field, efficacy, safety, standardization and strategy of AIT are being continuously developed...
October 3, 2017: Human Vaccines & Immunotherapeutics
keyword
keyword
15390
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"